Related Experiment Videos
New adjunctive therapy for ischemic syndromes
1Cardiovascular Intensive Care Unit, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas, USA. mdejong@aol.com
Critical Care Nursing Clinics of North America
|April 29, 2000
Summary
Anticoagulant and GP IIb/IIIa inhibitors are standard care for unstable angina (USA) and non-ST elevation myocardial infarction (NSTEMI), reducing mortality and complications. Further research is needed on optimal use and long-term benefits.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Anticoagulant and GP IIb/IIIa inhibitors are increasingly used for acute coronary syndromes.
- These agents have demonstrated significant reductions in mortality and ischemic events.
Purpose of the Study:
- To review the current standard of care for patients with unstable angina (USA) and non-ST elevation myocardial infarction (NSTEMI).
- To highlight ongoing research and unanswered questions regarding these pharmacologic agents.
Main Methods:
- Literature review of clinical trials and guidelines.
- Synthesis of current evidence on anticoagulant and GP IIb/IIIa inhibitor therapy.
Main Results:
- These agents are standard of care, reducing mortality, myocardial ischemia, acute myocardial infarction (AMI), and reintervention.
- Optimal treatment regimens, dosing, long-term benefits, and cost-effectiveness require further investigation.
Conclusions:
- Anticoagulant and GP IIb/IIIa inhibitors are crucial in managing USA and NSTEMI.
- Continued research and nursing involvement are vital for advancing ischemic heart disease prevention.